Method of treating certain eye diseases
OwnerGerard M. Nolaninventor
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for treating diminished visual acuity in a human patient who has been diagnosed as suffering from a disease or disorder of the posterior region of the eye. These involve topical application to the eye, an amount of acetylcholine esterase inhibitor containing composition is carried out so that it is sufficient to provide a therapeutic benefit to alleviate the diminished visual acuity in the human patient. The composition is administered at bedtime after an eye straining work for about 20 minutes.
Claims47
A method of treating a human eye disease, the method comprising topically administering to an eye affected with the disease, an amount of a composition consisting essentially of an acetylcholine esterase inhibitor sufficient to provide a therapeutic benefit, wherein the eye disease is age related macular degeneration, macular cyst, macular hole, solar retinopathy, diabetic retinopathy, branch retinal vein occlusion, or Lebers Congenital Amaurosis.
A method of treating an eye disease of a patient which comprises topically administering to an eye affected with the disease, an amount of a composition consisting essentially of (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate sufficient to provide a therapeutic benefit, wherein the eye disease is age related macular degeneration, macular cyst, macular hole, solar retinopathy, diabetic retinopathy, branch retinal vein occlusion, or Lebers Congenital Amaurosis and wherein the composition has (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate content of 0.001% to about 0.25%.
A method of treating an eye disease of a patient which comprises topically administering to an eye affected with the disease, an amount of a composition consisting essentially of (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate sufficient to provide a therapeutic benefit, wherein the eye disease is age related macular degeneration, macular cyst, macular hole, solar retinopathy, diabetic retinopathy, branch retinal vein occlusion, or Lebers Congenital Amaurosis and wherein the composition has (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate content of about 0.03%.
A method of treating a disease or disorder of the posterior region of the eye, the method comprising topically administering to the eye, an amount of a composition consisting essentially of (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate sufficient to provide a therapeutic benefit to alleviate the diminished visual acuity in the human patient, wherein the composition has (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate content of about 0.03% wherein said composition is administered at bedtime.
A method of treating a human patient suffering from an eye disease, the method comprising topically administering to the eye affected with the disease, a composition consisting essentially of an amount of (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate sufficient to provide a therapeutic benefit, wherein the eye disease is age related macular degeneration, macular cyst, macular hole, solar retinopathy, diabetic retinopathy, branch retinal vein occlusion, or Lebers Congenital Amaurosis and wherein the composition has (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate content of about 0.03% and wherein said composition administered at bedtime.
Dependencies are inferred from the claim text.